Calidi Biotherapeutics Inc. (CLDI)

US · Healthcare · Biotechnology

$1.27+8.55%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-4.2M

EPS

$-2.94

Market cap

$3.2M

Forward P/E

0.0

P/B

1.02

Book value

$1.50

EPS (TTM)

$-37.04

52-week high

$27.84

52-week low

$1.17

50-day MA

$1.63

200-day MA

$7.86

Beta

1.32

Analysts rate Calidi Biotherapeutics Inc. a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $120.00.

Insiders

0.87%

Institutions

1.42%

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Calidi Biotherapeutics Inc. — free to start.

Data updated 2026-09-18.